BioMed Research International / 2019 / Article / Tab 2

Research Article

Transarterial Chemoembolization (TACE) Combined with Sorafenib in Treatment of HBV Background Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Propensity Score Matching Study

Table 2

Baseline demographic and clinical characteristics of two propensity-matched groups (n=207).

CharacteristicTACE+sorafenib  
(n=69)
TACE  
(n=168)
X2/t/z  
Value
P Value

Age50.85±11.5251.4±11.20-0.3570.722
Sex
 Male591170.0190.890
 Female1021
Child-Pugh
 A671330.0740.786
 B25
AFP12307.24±20255.8813774.00±21995.32-0.4640.343
Number
 <3581730.0090.925
 ≥31134
Size8.39±4.458.55±3.39-0.2850.795
Type
 I/II43880.0420.838
 III/IV2650
Treatment after TACE
 surgery120.0850.958
 RFA13
 radiotherapy26

p<0.05

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.